REFERENCES
1. Piano S, Bunchorntavakul C, Marciano S, Rajender Reddy K. Infections in cirrhosis. Lancet Gastroenterol Hepatol. 2024;9:745-57.
2. Cullaro G, Sharma R, Trebicka J, Cárdenas A, Verna EC. Precipitants of acute-on-chronic liver failure: an opportunity for preventative measures to improve outcomes. Liver Transpl. 2020;26:283-93.
3. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385-96.
4. Cai J, Yip TC, Wong GL, et al. Global epidemiology of bacterial infections in patients with cirrhosis: a systematic review and meta-analysis. J Hepatol. 2026;84:1089-101.
5. Turner AM, Li L, Monk IR, et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature. 2024;635:969-77.
6. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis. 2007;45:S177-83.
7. Giamarellou H, Galani L, Karavasilis T, Ioannidis K, Karaiskos I. Antimicrobial stewardship in the hospital setting: a narrative review. Antibiotics. 2023;12:1557.
